Incremental Benefit of Open-Label Certolizumab Pegol plus MTX in Rheumatoid Arthritis (RA) Patients Following Double-Blind Placebo plus IVITX Treatment Out to 2 Years

Author(s):
Combe, B.; Schwartzman, S.; Massarotti, E.; Keystone, E.; Luijtens, K.; Heijde, D. van der
Published
2010
Publication type
Other
Date issued
2010-06-30
Language
English
hdl
1887/116820